OTCQB: GTBP

Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline

About

GT Biopharma, Inc. a targeted immunotherapies company with close to market treatments for Central Nervous System diseases.

About

Latest News

GT Biopharma Presents Positive Preclinical Data of Tri-specific NK Cell Engager (TriKE) at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition
Dec 6, 2018 • 8:05 EST | Read More

GT Biopharma Announces Presentation of Two Abstracts at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition
Nov 20, 2018 • 7:30 EST | Read More

Investors

GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range